Contract development and manufacturing organization (CDMO) Cambrex announced on Monday that its subsidiary Snapdragon Chemistry has expanded its active pharmaceutical ingredient facility in Waltham, Massachusetts, increasing capacity for peptide therapy development and manufacturing.

The investment adds a GMP manufacturing suite, raising the site's footprint by 20%. Enhancements include an ISO-7 cleanroom for preparative HPLC chromatography and lyophilization, along with upgraded raw material and product storage capabilities.

Snapdragon can now deliver peptide projects from early development through GMP manufacturing, employing solid-phase, liquid-phase, or hybrid synthesis. Its liquid-phase peptide synthesis technology reduces reliance on specialised reactors, lowering solvent use and excess reagent demand compared with traditional solid-state methods.

Cambrex continues to advance R&D in complex synthetic modalities, with ongoing work in peptide innovation and artificial intelligence applications for oligonucleotide process optimisation.